ASCO Presentations Show Hyperthermia Enhances Cancer Drug Delivery

SAN FRANCISCO, May 17, 2001—BSD Medical Corp. (OTCBB:BSDM). Hyperthermia dramatically increases the uptake of chemotherapy drugs by cancer cells. This message was repeated at the American Society of Clinical Oncologists (ASCO) just concluded, the largest medical convention in the world, with over 30,000 physicians and other medical attendance. According to a research team from Munich, this boost in the effectiveness of chemotherapy is good news for victims of high-risk soft-tissue sarcomas, one of the deadliest and most forms of cancer. It is also good news for treatment of breast cancer, according to a recent study from the University of California, San Francisco and another from Athens, Greece, and for ovarian cancer, where clinical trials underway at Duke University point to new breakthroughs.

When the temperature of tumors is raised to high-fever level (hyperthermia), tumors become more absorbent to chemotherapy drugs. Increased blood flow is the body’s natural response raising the uptake of drugs in tumor membranes. As a result, hyperthermia “increases antitumor efficacy in patients,” according to the UCSF team. Once drugs are delivered, they can also be used as an activator to accelerate drug chemical reactions. Hyperthermia is further demonstrated as a role as a valuable companion therapy when chemotherapy drugs are injected into the blood in encapsulated form (liposomes). Research has shown that when a liposome-encapsulated form demonstrates a role as a valuable companion therapy when chemotherapy drugs are injected into the blood in encapsulated form (liposomes). Research has shown that when a liposome-encapsulated form is used in combination with hyperthermia, tumor drug penetration greatly increases.

Dr. Rolf Issels of Munich University Medical School and GSF National Research Center for Oncology and Health made an advanced private presentation of his team’s important paper at a symposium sponsored by BSD Medical Corporation. Accompanying him were Dr. Zeljko Vujaskovic of Duke University Medical Center and Dr. Joan Bull of the University of Texas, Houston Health Science Center, who also gave a private review of her paper in advance of formal presentation. Vujaskovic reviewed research with liposomes and hyperthermia, and the use of hyperthermia in heat mediated gene therapy at Duke University. Dr. Bull focused on the important enhancement of hyperthermia in fighting metastasis.

Hyrum A. Mead, President of BSD Medical Corporation said, “We are very pleased with the growing interest in use of hyperthermia in combination with chemotherapy. In fact, a significant number of clinical oncologists in America have personally requested information from BSD about our private symposium, and several of those who attended are already pursuing BSD hyperthermia systems.”

BSD Medical Corporation [BSDM] is the leading developer of hyperthermia systems for cancer therapy and pioneer of non-surgical benign prostate treatment using microwave energy. For information on BSD Medical, or to find hyperthermic oncology information sources and treatment centers, visit our website (wwwbsdmc.com).

To automatically receive all Press Releases via email